Journal Clinical Psychiatry and Cognitive Psychology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal Clinical Psychiatry and Cognitive Psychology (2025) Volume 9, Issue 2

Psychiatric Comorbidities and Cognitive Dysfunction in Post-Traumatic Stress Disorder

Liana Brooks *

Department of Cognitive and Behavioral Science, Pacific University for Psychology, California, USA

*Corresponding Author:
Liana Brooks
Department of Cognitive and Behavioral Science
Pacific University for Psychology,
USA
E-mail:l.brooks@mindscience.org

Received:27-May-2025,Manuscript No.AACPCP-25-167449; Editor assigned:01-Jun-2025,PreQC No.AACPCP-25-167449(PQ); Reviewed:15-Jun-2025,QC No.AACPCP-25-167449; Revised:22-Jun-2025,Manuscript No.AACPCP-25-167449(R); Published:29-Jun-2025,DOI: 10.35841/aacpcp-9.2.219

Citation: Brooks L. Psychiatric Comorbidities and Cognitive Dysfunction in Post-Traumatic Stress Disorder. Cogn Psychol. 2025; 9(2):219

Introduction

Post-Traumatic Stress Disorder (PTSD) is a debilitating psychiatric condition that arises following exposure to traumatic events. Beyond its hallJunk symptoms—intrusive memories, hyperarousal, avoidance, and negative mood—PTSD frequently co-occurs with other psychiatric disorders and is often associated with cognitive dysfunction. These comorbidities and cognitive impairments not only complicate diagnosis and treatment but also significantly affect the quality of life and daily functioning of individuals with PTSD [1, 2, 3, 4, 5].

Common psychiatric comorbidities in PTSD include depression, anxiety disorders, and substance use disorders. These conditions can mask or amplify PTSD symptoms, creating a complex clinical picture. For instance, depression can exacerbate emotional numbness, while anxiety may heighten hypervigilance. Substance use, often a coping mechanism, can lead to poor treatment adherence and worsened outcomes [6, 7, 8].

Cognitive dysfunction in PTSD typically affects attention, working memory, and executive functioning [9, 10]. Neurobiological studies suggest that changes in the hippocampus, amygdala, and prefrontal cortex contribute to these impairments. Such deficits hinder emotional regulation, learning, and problem-solving, thereby impairing social and occupational functioning.

Conclusion

The interplay between psychiatric comorbidities and cognitive dysfunction in PTSD presents significant clinical challenges. A comprehensive treatment approach that addresses both the psychological and cognitive aspects is crucial for improving patient outcomes. Early intervention, cognitive rehabilitation, and integrated therapy models are vital steps toward holistic recovery in individuals living with PTSD.Top of Form

References

  1. Evans M, Wilkinson M, Giannpolou A. Fast-acting insulin aspart: the rationale for a new mealtime insulin. Diabetes Therapy. 2019;10:1793-800.
  2. Giorgino F, Battelino T, Bergenstal RM, et al. The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus. Journal of Diabetes Science and Technology. 2023:19322968231204584.
  3. Hoogwerf BJ, Pantalone KM, Basina M, et al. Results of a 24-week trial of technosphere insulin versus insulin aspart in type 2 diabetes. Endocr Pract. 2021;27(1):38-43.
  4. Glastras SJ, Cohen N, Dover T, et al. The clinical role of insulin degludec/insulin aspart in type 2 diabetes: an empirical perspective from experience in Australia. J. Clin. Med.ine. 2020;9(4):1091.
  5. Shah VN, Al?Karadsheh A, Barnes C, et al. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. Diabetes Obes. 2023.
Get the App